Setmelanotide monoacetate

Synonyms: RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate
Setmelanotide monoacetate (RM-493 monoacetate) 是一种可透过血脑屏障的选择性 MC4R 激动剂,对 hMC4R 的 Ki 值为 2.1 nM,可激活 CaMKK2/AMPK 信号通路,并通过介导体重稳态、摄食调控与能量消耗调节来减少摄食量、诱导体重减轻、降低肥胖程度、增加日间活动量与能量消耗、降低瘦素、甘油三酯、空腹胰岛素水平及舒张压、改善胰岛素敏感性、葡萄糖耐量与脂肪肝病情以及逆转呼吸抑制,从而可用于肥胖症、高胰岛素血症、脂肪肝及呼吸抑制相关研究。
产品编号: MS-H39637 纯度: 99.81% CAS No.: 2759937-80-7 分子式: C51H72N18O11S2 分子量: 1177.36
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Setmelanotide monoacetate (RM-493 monoacetate) 是一种可透过血脑屏障的选择性 MC4R 激动剂,对 hMC4R 的 Ki 值为 2.1 nM,可激活 CaMKK2/AMPK 信号通路,并通过介导体重稳态、摄食调控与能量消耗调节来减少摄食量、诱导体重减轻、降低肥胖程度、增加日间活动量与能量消耗、降低瘦素、甘油三酯、空腹胰岛素水平及舒张压、改善胰岛素敏感性、葡萄糖耐量与脂肪肝病情以及逆转呼吸抑制,从而可用于肥胖症、高胰岛素血症、脂肪肝及呼吸抑制相关研究。

生物实验数据

生物活性 Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable selective MC4R agonist with a Ki of 2.1 nM for hMC4R that activates the CaMKK2/AMPK signaling pathway and, by mediating body weight homeostasis, feeding regulation, and energy expenditure regulation, reduces food intake, induces weight loss, decreases obesity, increases daytime activity and energy expenditure, lowers leptin, triglyceride, fasting insulin, and diastolic blood pressure levels, improves insulin sensitivity, glucose tolerance, and fatty liver disease, and reverses respiratory depression, and can therefore be used in research related to obesity, hyperinsulinemia, fatty liver disease, and respiratory depression.
IC50 & Target MC3R (human): 5.3nM (EC50), MC3R (human): 10 nM (ki), MC5R (human): 430 nM (ki), MC4R (human): 0.27 nM (EC50), MC5R (human): 1600 nM (EC50), MC1R (human):5.8 nM (EC50), MC4R (rat):0.28 Nm (EC50), MC1R (human):3.9 nM (ki), MC4R (rat): 2.7 nM (ki), MC4R (human): 2.1 nM (ki)
体外研究
(In Vitro)

Setmelanotide monoacetate 可高亲和力结合 hMC1R、MC3R、MC4R 及大鼠 MC4R,与 hMC5R 的结合亲和力较弱。
Setmelanotide (浓度递增;37°C 条件下作用 40 min) monoacetate 可作为激动剂,刺激表达 hMC1R、hMC3R、hMC4R 及大鼠 MC4R 的 CHO-K1 细胞产生 cAMP;其在 hMC5R 上活性较弱,在小鼠 MC2R 上无活性。
Setmelanotide monoacetate 是 hMC4R 的强效激动剂,在 CHO-K1 细胞中的结合 Ki 为 2.1 nM,cAMP EC50 为 0.27 nM,且对 hMC1R、hMC3R 和 hMC5R 的效力较低。
Setmelanotide (>1.0×10−6 M) monoacetate 对 μ-阿片受体无亲和力,因其在竞争性放射性配体结合试验中的 IC50 超过 1.0×10−6 M。

体内研究
(In Vivo)

Setmelanotide (300 nmol/kg/天;皮下注射;持续;14 天) monoacetate 可诱导饮食诱导肥胖 C57BL/6J 小鼠减重、改善高胰岛素血症、降低总胆固醇和瘦素水平,并逆转肝脏脂肪变性。
Setmelanotide (6.4 μmol;腹腔注射;单次) monoacetate 可急性改善瘦素缺陷型肥胖、糖耐量异常 C57BL/6J 小鼠的葡萄糖清除能力。
Setmelanotide (6.4 μmol;腹腔注射;单次) monoacetate 可抑制饲喂普通饲料的 C57BL/6J 小鼠因再进食产生的摄食量,该效应依赖于功能性 MC4R 而非 MC3R。
Setmelanotide (0.17-0.5 mg/kg/day;通过每两周一次的 2 周微型泵给予;持续 8 周或时长可变) monoacetate 可使饮食诱导肥胖的恒河猴体重峰值下降 13.5%,改善胰岛素敏感性与心血管功能,且不会引发心率或血压的不良升高;而较低剂量仅能改善胰岛素敏感性,对体重或心血管参数的影响极小。
Setmelanotide (0.05 mg/kg;腹腔注射;单次) monoacetate 可通过 CaMKK2/AMPK 信号通路激活 PVN MC4R 神经元,从而使下丘脑性肥胖大鼠短期再进食的食物摄入恢复正常。
Setmelanotide (0.05 mg/kg;腹腔注射;每日 1 次) monoacetate 可通过 CaMKK2/AMPK 信号通路激活 PVN MC4R 神经元,减少摄食量、体重、Lee 指数及肾周脂肪组织重量,从而逆转大鼠下丘脑性肥胖。
Setmelanotide (6.4 µmole-1.34 mg/kg/day;腹腔注射、皮下注射;单次注射、每日;持续 14 天) monoacetate 可在饮食诱导肥胖小鼠中引发 MC4R 依赖性的摄食抑制与体重下降。
Setmelanotide (100-500 nmol/kg;皮下注射;单次) monoacetate 抑制禁食雄性 Sprague-Dawley 大鼠的摄食量。
Setmelanotide (1 mg/kg;腹腔注射;单次) monoacetate 可通过提高呼吸频率、降低呼吸暂停指数有效治疗瘦型雄性 C57BL/6J 小鼠中吗啡诱导的阿片类化合物诱导的呼吸抑制 (OIRD),且不会损害阿片类镇痛作用。
Setmelanotide (1 mg/kg;腹腔注射;单次) monoacetate 可通过提高呼吸频率、降低呼吸暂停的频率和时长,在不影响阿片类镇痛作用的前提下,有效治疗肥胖雄性 C57BL/6J 小鼠中吗啡诱导的阿片类化合物相关呼吸抑制。

Animal Model: C57BL/6J (male, 10 months old, diet-induced obese)
Dosage: 300 nmol/kg/day
Administration: s.c.; continuous; 14 days
Result: Reduced food intake to ~50% of controls on day 1, increasing to 75% of control levels by day 4, with no significant difference by day 12.
Lowered fasting serum insulin, glucose, and HOMA-IR values significantly.
Reduced serum leptin and total cholesterol levels significantly.
Improved liver steatosis significantly (P < 0.05).
Increased liver-specific Cpt1a expression modestly but significantly.
Animal Model: C57BL/6J (male, 10 months old, leptin-deficient)
Dosage: 6.4 μmol
Administration: i.p.; single injection
Result: Improved glucose clearance significantly compared to saline-treated controls.
Animal Model: C57BL/6J (female, 10 months old; wild-type, MC3R knockout, MC4R knockout littermates)
Dosage: 6.4 μmol
Administration: i.p.; single injection
Result: Inhibited refeeding-induced food intake in WT and MC3RKO mice.
Showed no inhibitory effect on refeeding-induced food intake in MC4RKO mice.
Animal Model: mature adult male (age 9-11 years, body weight 9-19 kg; 9 diet-sensitive/obese, insulin-resistant, hypertensive; 3 diet-resistant/lean, normotensive)
Dosage: 0.5 mg/kg/day (8-week treatment); 0.17 mg/kg/day (subsequent treatment period)
Administration: s.c.; via biweekly 2-week minipumps; 8 weeks (0.5 mg/kg/day); variable duration (0.17 mg/kg/day)
Result: Decreased food intake by 35% in the first week, normalized by weeks 4-7, and increased during week 8.
Reached peak weight loss of 13.5% of total body weight (average 1.5 kg lost over 8 weeks), with weight loss persisting for 2 weeks post-treatment before recovery began.
Nearly doubled daytime activity by treatment end (P = 0.037, repeated-measures ANOVA).
Increased energy expenditure (CO2 production) by 14% (P = 0.0134, paired t-test) compared to baseline.
Decreased core body temperature by ~0.5°C (P = 0.0161, repeated-measures ANOVA).
Reduced fat mass by 18.8% (1.04 kg) in diet-sensitive animals and 38.3% (0.75 kg) in diet-resistant animals; fat mass remained significantly reduced in diet-sensitive animals post-washout.
Decreased lean mass by 4.9% in diet-sensitive animals.
Decreased fasting leptin levels significantly in diet-sensitive animals (P < 0.001), with the magnitude of leptin decrease correlating with weight loss (r2 = 0.6634, P = 0.0023).
Reduced fasting serum triglyceride levels significantly at 8 weeks (P = 0.0238, ANOVA).
Improved fasting insulin levels and homeostasis model assessment insulin resistance significantly in diet-sensitive animals, with reduced insulin secretion (area under the curve) and improved glucose clearance (area under the curve) during intravenous glucose tolerance testing; these improvements persisted for 4 weeks post-treatment.
Decreased heart rate significantly overall (P = 0.008, repeated-measures ANOVA), with a 13-bpm reduction in diet-sensitive animals, and reduced diastolic blood pressure significantly (P = 0.02, repeated-measures ANOVA); systolic blood pressure was unchanged.
No acute increases in heart rate or blood pressure were observed.
Improved insulin sensitivity with smaller effects on food intake and body weight at 0.17 mg/kg/day.
No changes to blood pressure or heart rate were observed at 0.17 mg/kg/day.
Animal Model: Sprague-Dawley (male)
Dosage: 100 nmol/kg; 500 nmol/kg
Administration: s.c.; single injection
Result: Reduced food intake during refeeding after an overnight fast at both 100 nmol/kg and 500 nmol/kg doses.
性状 固体
颜色 White to off-white

化学信息

分子量 1177.36
分子式 C51H72N18O11S2
CAS No. 2759937-80-7
别名 RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (1.7 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (84.94 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.8494 mL4.2468 mL8.4936 mL21.2339 mL
5 mM0.1699 mL0.8494 mL1.6987 mL4.2468 mL
10 mM0.0849 mL0.4247 mL0.8494 mL2.1234 mL
15 mM0.0566 mL0.2831 mL0.5662 mL1.4156 mL
20 mM0.0425 mL0.2123 mL0.4247 mL1.0617 mL
25 mM0.0340 mL0.1699 mL0.3397 mL0.8494 mL
30 mM0.0283 mL0.1416 mL0.2831 mL0.7078 mL
40 mM0.0212 mL0.1062 mL0.2123 mL0.5308 mL
50 mM0.0170 mL0.0849 mL0.1699 mL0.4247 mL
60 mM0.0142 mL0.0708 mL0.1416 mL0.3539 mL
80 mM0.0106 mL0.0531 mL0.1062 mL0.2654 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础